Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An update from Cogstate Ltd ( (AU:CGS) ) is now available.
Cogstate Ltd has released an unaudited business update for the half-year ending December 2024, indicating its financial performance, with detailed information available in an investor presentation. The finalized audited results will be announced in February 2025. This update reflects Cogstate’s ongoing efforts to enhance its market position in the neuroscience technology sector and its commitment to stakeholders by providing transparency on its financial status.
More about Cogstate Ltd
Cogstate Ltd is a neuroscience technology company that specializes in optimizing brain health assessments to support the development of new medicines and facilitate earlier clinical insights in healthcare. The company offers computerized cognitive tests and electronic clinical outcome assessment solutions, focusing on replacing traditional paper assessments with real-time data capture. Cogstate collaborates with biopharmaceutical companies, academic institutions, and healthcare providers worldwide, and has partnered with Eisai for distribution in the USA and Asia.
YTD Price Performance: 0.29%
Average Trading Volume: 16,598
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $115.5M
See more insights into CGS stock on TipRanks’ Stock Analysis page.
